comparemela.com

Latest Breaking News On - Belapectin program - Page 1 : comparemela.com

Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update

29.03.2024 - NORCROSS, Ga., March 29, 2024 (GLOBE NEWSWIRE) - Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended .

Richard uihleinChris calabreseJack callicuttKhurram jamilKevin gardnerBenjamins carsonPol boudesCompany annual report on formBelapectin programDrug administrationCompany contactExchange commissionGalectin therapeutics incChief medical officerFast track designationData safety

Galectin Therapeutics : Reports 2023 Financial Results and Provides Business Update - Form 8-K -March 29, 2024 at 07:59 am EDT

Galectin Therapeutics, Inc. , the leading developer of therapeutics that target galectin proteins, today reported financial results and provided a business update for the year ended December 31,.

Khurram jamilChris calabreseBenjamins carsonJack callicuttJoel lewisPol boudesRichard uihleinKevin gardnerCompany annual report on formExchange commissionCompany contactBelapectin programDrug administrationGalectin therapeutics incGalectin therapeutics reportsProvides business update

vimarsana © 2020. All Rights Reserved.